BUILDING SAFER AND MORE POTENT TREATMENTS
OUR SOLUTION
Deliver medicines that target cell surface protein communities.
DISCOVERY
Cells build unique protein complexes on their surfaces. The science of a cell’s Surfaceome is just beginning to be understood, but it is clear that this network of interacting proteins is critical to all cells. Additionally, these communities are cell type specific.
Centrose discovered that one protein, encoded by the ATP1A1 gene and called the NKA, interacts with many important cell signalling proteins. This makes the NKA a very important drug target, but science passed it up because it is hidden and found on all cells. Now with EDC Technology, Centrose has been able to target the NKA in a cell type specific manner.
EDC Technology allows the modulation of the NKA only when it interacts with specific communities of other proteins. Centrose went on to discover that EDC therapies can destroy cancers by a process known as “necrosis” while leaving normal cells untouched. It has been shown for years that inhibitors of the NKA also overcome drug resistance, and by targeting these drugs using EDCs, you can induce immune responses, an important goal when treating patients with check-point inhibitors like Yervoy and Keytruda.
REPORTS
As we reported in our cell press publication, Centrose discovered that drug targets like CD20, CD38 and many others were interacting with the NKA. The idea that antibodies like Rituxan could precisely deliver powerful cancer drugs to CD20+ B-cells only led to the discovery of EDC Technology.
The Centrose PIPELINE
EDC9 targets B-Cells and will initially be tested on patients with drug resistant Non-Hodgkin's Lymphomas (NHL).
EDC1 kills cells that express a protein called dysadherin, which allows cancers to spread and alpha cells to grow.
EDC8 targets CD38-dysadherin complexes (a complex found on Acute Myeloid Leukemia cells) and destroys them while leaving normal cells untouched.
